Business Context and Reporting Period
This Form 8-K Current Report from CalciMedica, Inc. (Nasdaq: CALC) covers events occurring on June 24, 2025, specifically the company's 2025 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, and amendments to the equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
As of the record date (April 28, 2025), 13,971,990 shares of common stock were outstanding and entitled to vote. The following material actions were approved by stockholders:
- Director Elections (Proposal 1): Stockholders elected three Class II directors to serve three-year terms through the 2028 annual meeting:
- Rachel Leheny, Ph.D.: 9,581,539 votes for; 274,011 withheld.
- Eric W. Roberts: 9,556,244 votes for; 299,306 withheld.
- Frederic Guerard, Pharm.D.: 9,556,839 votes for; 298,711 withheld.
- Auditor Ratification (Proposal 2): Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 12,275,925
- Votes Against: 135,495
- Abstentions: 40
- Equity Plan Amendment (Proposal 3): Stockholders approved an amendment to the Amended 2023 Equity Incentive Plan to increase the number of authorized shares by 600,000.
- Votes For: 8,917,965
- Votes Against: 923,840
- Abstentions: 13,745
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The primary focus is the administrative completion of the Annual Meeting and the formal approval of the equity plan amendment, which was previously approved by the Board of Directors on April 23, 2025.
Key Facts for Investor Verification
- Verify the impact of the 600,000 share increase to the 2023 Equity Incentive Plan on potential future dilution.
- Review the definitive proxy statement (Schedule 14A) filed on April 29, 2025, for detailed terms of the amended equity plan.
- Confirm the tenure of the newly elected directors (Rachel Leheny, Eric Roberts, Frederic Guerard) extending through 2028.
- Note that Baker Tilly US, LLP has been retained as the independent auditor for the fiscal year ending December 31, 2025.